Wang, Jingxin published the artcileMechanistic studies of a small-molecule modulator of SMN2 splicing, Quality Control of 91678-81-8, the main research area is SMN2 gene splicing FUBP1 cloning sequence spinal muscular atrophy; SMNC2 SMNC3 drug synthesis RG7916 therapy SMA human; RG-7916; RNA binding; RNA splicing; chemical proteomics; spinal muscular atrophy.
RG-7916 is a first-in-class drug candidate for the treatment of spinal muscular atrophy (SMA) that functions by modulating pre-mRNA splicing of the SMN2 gene, resulting in a 2.5-fold increase in survival of motor neuron (SMN) protein level, a key protein lacking in SMA patients. RG-7916 is currently in three interventional phase 2 clin. trials for various types of SMA. In this report, we show that SMN-C2 and -C3, close analogs of RG-7916, act as selective RNA-binding ligands that modulate pre-mRNA splicing. Chem. proteomic and genomic techniques reveal that SMN-C2 directly binds to the AGGAAG motif on exon 7 of the SMN2 pre-mRNA, and promotes a conformational change in two to three unpaired nucleotides at the junction of intron 6 and exon 7 in both in vitro and in-cell models. This change creates a new functional binding surface that increases binding of the splicing modulators, far upstream element binding protein 1 (FUBP1) and its homolog, KH-type splicing regulatory protein (KHSRP), to the SMN-C2/C3-SMN2 pre-mRNA complex and enhances SMN2 splicing. These findings underscore the potential of small-mol. drugs to selectively bind RNA and modulate pre-mRNA splicing as an approach to the treatment of human disease.
Proceedings of the National Academy of Sciences of the United States of America published new progress about Animal gene Role: BSU (Biological Study, Unclassified), PRP (Properties), BIOL (Biological Study) (TSL1). 91678-81-8 belongs to class pyrazines, name is 3,5-Dimethylpyrazin-2-amine, and the molecular formula is C6H9N3, Quality Control of 91678-81-8.